Discovery Laboratories begins and halts Phase IIIs

DSCO began U.S. Phase III testing of its Surfaxin pulmonary surfactant in 200 newborns with meconium aspiration syndrome. The study will compare Surfaxin to standard care. Separately, DSCO halted its ...